Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses J Sarris, J Murphy, D Mischoulon, GI Papakostas, M Fava, M Berk, CH Ng Focus 16 (3), 328-340, 2018 | 387 | 2018 |
Adjunctive nutraceuticals for depression: a systematic review and meta-analyses J Sarris, J Murphy, D Mischoulon, GI Papakostas, M Fava, M Berk, CH Ng American Journal of Psychiatry, 2016 | 379 | 2016 |
Prevalence and correlates of the proposed DSM-5 diagnosis of chronic depressive disorder JA Murphy, GJ Byrne Journal of affective disorders 139 (2), 172-180, 2012 | 214 | 2012 |
N-acetyl cysteine (NAC) in the treatment of obsessive-compulsive disorder: A 16-week, double-blind, randomised, placebo-controlled study J Sarris, G Oliver, DA Camfield, OM Dean, N Dowling, DJ Smith, J Murphy, ... CNS drugs 29 (9), 801-809, 2015 | 88 | 2015 |
A Review of the Conceptualisation and Risk Factors Associated with Treatment-Resistant Depression JA Murphy, J Sarris, GJ Byrne Depression research and treatment 2017, 2017 | 76 | 2017 |
L-theanine in the adjunctive treatment of generalized anxiety disorder: A double-blind, randomised, placebo-controlled trial J Sarris, GJ Byrne, L Cribb, G Oliver, J Murphy, P Macdonald, S Nazareth, ... Journal of psychiatric research 110, 31-37, 2019 | 69 | 2019 |
Kava for the treatment of generalised anxiety disorder (K-GAD): study protocol for a randomised controlled trial KM Savage, CK Stough, GJ Byrne, A Scholey, C Bousman, J Murphy, ... Trials 16 (1), 1, 2015 | 60 | 2015 |
Nutraceuticals for Major Depressive Disorder-More is Not Merrier: an 8-week double-blind, randomized, controlled trial J Sarris, GJ Byrne, C Stough, C Bousman, D Mischoulon, J Murphy, ... Journal of Affective Disorders, 2018 | 58 | 2018 |
Kava for generalised anxiety disorder: A 16-week double-blind, randomised, placebo-controlled study J Sarris, GJ Byrne, CA Bousman, L Cribb, KM Savage, O Holmes, ... Australian & New Zealand Journal of Psychiatry 54 (3), 288-297, 2020 | 44 | 2020 |
Adjunctive S-adenosylmethionine (SAMe) in treating non-remittent major depressive disorder: An 8-week double-blind, randomized, controlled trial J Sarris, GJ Byrne, C Bousman, C Stough, J Murphy, P MacDonald, ... European Neuropsychopharmacology, 2018 | 34 | 2018 |
EPA and DHA as markers of nutraceutical treatment response in major depressive disorder KP van der Burg, L Cribb, J Firth, D Karmacoska, D Mischoulon, GJ Byrne, ... European journal of nutrition 59 (6), 2439-2447, 2020 | 25 | 2020 |
EPA and DHA as markers of nutraceutical treatment response in major depressive disorder KP Burg, L Cribb, J Firth, D Karamacoska, D Mischoulon, GJ Byrne, ... European Journal of Nutrition, 2439-2447, 2020 | 25 | 2020 |
S-Adenosylmethionine (SAMe) monotherapy for depression: an 8-week double-blind, randomised, controlled trial J Sarris, J Murphy, C Stough, D Mischoulon, C Bousman, P MacDonald, ... Psychopharmacology 237 (1), 209-218, 2020 | 25 | 2020 |
Erythrocyte polyunsaturated fatty acid composition is associated with depression and FADS genotype in Caucasians L Cribb, J Murphy, A Froud, G Oliver, CA Bousman, CH Ng, J Sarris Nutritional Neuroscience, 1-13, 2017 | 25 | 2017 |
The relationship between dietary quality, serum brain-derived neurotrophic factor (BDNF) level, and the Val66met polymorphism in predicting depression A Froud, J Murphy, L Cribb, CH Ng, J Sarris Nutritional neuroscience, 1-9, 2017 | 22 | 2017 |
An adjunctive antidepressant nutraceutical combination in treating major depression: Study protocol, and clinical considerations J Sarris, C Stough, C Bousman, J Murphy, K Savage, DJ Smith, R Menon, ... Advances in Integrative Medicine 2 (1), 49-55, 2015 | 22 | 2015 |
Pilot-Testing of “Healthy Body Healthy Mind”: An Integrative Lifestyle Program for Patients With a Mental Illness and Co-morbid Metabolic Syndrome JA Murphy, G Oliver, CH Ng, C Wain, J Magennis, RS Opie, A Bannatyne, ... Frontiers in psychiatry 10, 91, 2019 | 17 | 2019 |
Treatment of refractory obsessive–compulsive disorder with nutraceuticals (TRON): a 20-week, open label pilot study J Sarris, GJ Byrne, G Oliver, L Cribb, S Blair-West, D Castle, OM Dean, ... CNS spectrums, 1-10, 2021 | 6 | 2021 |
Mitochondrial modifying nutrients in treating chronic fatigue syndrome: A 16-week open-label pilot study R Menon, L Cribb, J Murphy, MM Ashton, G Oliver, N Dowling, A Turner, ... Advances in Integrative Medicine, 2017 | 6 | 2017 |
N-acetyl cysteine (NAC) augmentation in the treatment of obsessive-compulsive disorder: A phase III, 20-week, double-blind, randomized, placebo-controlled trial J Sarris, G Byrne, D Castle, C Bousman, G Oliver, L Cribb, S Blair-West, ... Progress in Neuro-Psychopharmacology and Biological Psychiatry 117, 110550, 2022 | 5 | 2022 |